TP53 and acute myeloid leukemia: Simvastatin pretreatment of AML cell lines with wild-type TP53+/+ or CAR T-cells did not show any effect on CAR T-cell efficacy, indicating that the effect is specific for TP53-deficient AML cells (Figs. 6D,E and EV5D).